Attached files
file | filename |
---|---|
8-K - FORM 8-K - ERESEARCHTECHNOLOGY INC /DE/ | c02037e8vk.htm |
EX-10.1 - EXHIBIT 10.1 - ERESEARCHTECHNOLOGY INC /DE/ | c02037exv10w1.htm |
EX-10.5 - EXHIBIT 10.5 - ERESEARCHTECHNOLOGY INC /DE/ | c02037exv10w5.htm |
EX-10.4 - EXHIBIT 10.4 - ERESEARCHTECHNOLOGY INC /DE/ | c02037exv10w4.htm |
EX-10.2 - EXHIBIT 10.2 - ERESEARCHTECHNOLOGY INC /DE/ | c02037exv10w2.htm |
EX-10.3 - EXHIBIT 10.3 - ERESEARCHTECHNOLOGY INC /DE/ | c02037exv10w3.htm |
Exhibit 99.1
ERT Closes the Acquisition of the
Research Services Division of CareFusion Corporation
Research Services Division of CareFusion Corporation
PHILADELPHIA, June 1, 2010/PRNewswire-FirstCall/ eResearchTechnology, Inc. (ERT), (Nasdaq:
ERES News), a global provider of technology and services to the pharmaceutical,
biotechnology, and medical device industries, announced the successful closing of the acquisition
of the Research Services Division of CareFusion Corporation (CRS). CRS is a leading provider of
respiratory diagnostics services and manufacturer of diagnostic devices and also offers cardiac
safety and ePRO services. The combined company offers a market leading position in the very
attractive clinical research market for cardiac safety services, cardiac safety consulting,
respiratory services, ePRO services, and medical devices. The acquisition will serve to diversify
ERTs revenue base, expand its global footprint, and increase the potential for development of new
services and products in clinical research and healthcare delivery.
As previously reported, ERT paid $80.8 million in cash for CRS after giving effect to preliminary
closing balance sheet adjustments. The acquisition was financed from ERTs existing cash and $23
million drawn from ERTs new $40 million revolving credit facility through Citizens Bank of
Pennsylvania. The credit facility was established on May 27, 2010.
ERT plans to issue updated forward-looking financial guidance for the second half of 2010 and for
the calendar year 2010 in conjunction with its release of earnings for the second quarter of 2010.
ERT will discuss the acquisition and the updated financial guidance during its earnings conference
call.
About eResearchTechnology, Inc.
Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com) is a global
provider of technology and services to the pharmaceutical, biotechnology, and medical device
industries. The Company is a market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical
development and centralized respiratory technology and services to evaluate pulmonary function
efficacy and safety in clinical development. The Company also provides technology and services to
streamline the clinical trials process by enabling its customers to automate the collection,
analysis, and distribution of electronic patient reporting outcomes clinical data in all phases of
clinical development as well as selected medical devices for the clinical trials and healthcare
industries.
www.ert.com | ||||||
eResearchTechnology, Inc.
|
1818 Market Street, Suite 1000 | 1150 U.S. Highway 22 East | eResearchTechnology Limited | |||
Philadelphia, PA 19103-3638 | Bridgewater, NJ 08807-2912 | Pegasus House, Bakewell Road | ||||
Main: +1 215.972.0420 | Main: +1 908.704.8010 | Orton Southgate, Peterborough PE2 6YS UK | ||||
Fax: +1 215.972.0414 | Fax: +1 908.704.8218 | Main: +44 1733 374800 | ||||
Fax: +44 1733 238782 |
This release may include forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 that reflect our current views as to future events and financial
performance with respect to our operations. These statements can be identified by the fact that
they do not relate strictly to historical or current facts. They use words such as aim,
anticipate, are confident, estimate, expect, will be, will continue, will likely
result, project, intend, plan, believe, look to and other words and terms of similar
meaning in conjunction with a discussion of future operating or financial performance.
These statements are subject to risks and uncertainties that could cause actual results to differ
materially from those expressed or implied in the forward-looking statements. Factors that might
cause such a difference include: unfavorable economic conditions; our ability to obtain new
contracts and accurately estimate net revenues, our positive outlook for future bookings,
variability in size, scope and duration of projects and internal issues at the sponsoring client;
our ability to successfully integrate acquisitions; competitive factors in the market for
centralized Cardiac Safety services and respiratory technology and services; changes in the
pharmaceutical, biotechnology and medical device industries to which we sell our solutions;
technological development; and market demand. There is no guarantee that the amounts in our backlog
will ever convert to revenue. Should the current economic conditions continue or deteriorate
further, the cancellation rates that we have historically experienced could increase. Further
information on potential factors that could affect the Companys financial results can be found in
the Companys Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date made. We undertake no obligation to update any
forward-looking statements, including prior forward-looking statements, to reflect the events or
circumstances arising after the date as of which they were made. As a result of these risks and
uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements
included in this release or that may be made in our filings with the Securities and Exchange
Commission or elsewhere from time to time by, or on behalf of, us.
Contact: |
||
Keith Schneck
|
Robert East | |
eResearchTechnology, Inc.
|
Westwicke Partners, LLC | |
215-282-5566
|
410-321-9652 |
www.ert.com
1.866.538.2808
1.866.538.2808